Tumeurs solides

  • Accueil
  • Tumeurs solides
  • CA244-0001

TITRE (EN) A Phase 1/2a, Open-label, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BMS-986507 (BL-B01D1) Combinations in Adult Participants With Advanced Solid Tumors
PROTOCOLE ID CA244-0001
CLINICAL TRIAL.gov ID NCT06618287
TYPE(S) DE CANCER Tumeurs solides
PHASE Phase I-II
TYPE D'ÉTUDE Clinique
INSTITUTION HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS
3755 rue de la Côte Ste. Catherine
(514) 340-8222
VILLE Montréal
INVESTIGATEUR(RICE) PRINCIPAL(E) Jennifer Friedmann
COORDONATEUR(RICE) Karima Khebab
karima.khebbab.ccomtl@ssss.gouv.qc.ca
514-340-8222 poste 26187
STATUT  Actif en recrutement
CRITÈRES D'ÉLIGIBILITÉ (EN)
  • Participants must have at least one measurable lesion per response evaluation criteria in solid tumors.
  • Participants must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1.
  • Participants must have a life expectancy of at least 3 months at the time of the first dose.
CRITÈRES D'EXCLUSION (EN)
  • Participants must not have any mixed Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC) histology.
  • Participants must not have any untreated symptomatic central nervous system (CNS) metastases.
  • Participants must not have a history of serious recurrent infections.
  • Participants must not have a history of severe heart disease.
  • Other protocol-defined Inclusion/Exclusion criteria apply.